

Anticancer evaluation of 4-substituted-*N*-(quinolin-8-yl)pyridine-3-sulfonamides

Krzysztof Szafranski^a, Jarosław Sławiński^a, Anna Kawiak^b

e-mail: krzysztof.szafranski@gumed.edu.pl



^a Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland

^b Department of Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, ul. Abrahama 58, 80-307 Gdańsk

Introduction:

During our research over biological activity of different *N*-aryl-pyridine-3-sulfonamides we have found that only compound bearing *N*-(quinolin-8-yl) substituent possess a significant anti-tumor activity (**Figure 1**).


Mechanisms of anticancer activity of *N*-(quinoline)sulfonamide derivatives and similar shaped molecules (**Figure 2**) was reported to be inhibition of NF-κB pathway [1,2,3]. Nuclear factor NF-κB regulates expression of genes that control cell proliferation and cell survival thus it is considered as potential molecular targets for the prevention and treatment of cancer. Based on this information we decided to synthesize and evaluate series of 4-amino-*N*-(quinolin-8-yl)pyridine-3-sulfonamides **5-8**, which contain both 8-aminquinolin group and pyridine-3-sulfonamide scaffold.



Synthesis:

The necessary substrates used in synthesis were obtained by sulfonation of 4-hydroxypyridine (**1**) and further reaction with PCl₅ and POCl₃, giving 4-chloropyridine-3-sulfonyl chloride (**3**), *N*-(quinolin-8-yl)-4-chloropyridine-3-sulfonamide (**4**) was obtained in reaction of **3** with 8-Aminoquinoline.

Target compounds **5-8** were obtained by aromatic nucleophilic substitution reaction of chlorine atom in position 4 of pyridine ring (**4**) with various amines. Structures of final compounds were confirmed using the spectroscopic methods: IR, ¹H NMR, and elemental analysis (C, H, N).



Conditions:

- H₂SO₄/SO₃, HgSO₄, 180°C, 24 h;
- PCl₅, POCl₃ reflux 24 h;
- 8-aminoquinoline, DIPEA, CH₂Cl₂, 0°C 1 h, r.t. 7 h
- R-NH₂, MeOH, reflux 2-26 h;




Table:

Cytotoxic activity of compounds 4-8

Comp.	IC ₅₀ [μM]			
	Cell line			
	HCT-116	HeLa	MCF-7	HaCaT
4	4.5	9	6.5	16
5	14	43	18	54
6	5	11	8	23
7	5	11	6	24
8	5	9	6	24
cisplatin	3.8	2.2	3	-

Biological studies:

Compounds **4-8** were submitted to test towards their effect on growth of human cancer cell lines: colon cancer HCT-116, breast cancer MCF-7, cervical cancer HeLa and *non*-tumorigenic human epidermal *HaCaT*. Cell viability was measured using MTT assay after 72 h of incubation with tested compound in concentrations 1 – 100 μM. Cytotoxic evaluation was reported as IC₅₀ – the concentration required for 50% inhibition of cell viability (**Table**).

New compounds were also analyzed with SwissADME Web Tool [4] to predict their bioavailability after oral administration in human organism.

The results of the calculations show that each of the compounds **4-8** meet the Lipiński's rules, moreover, the number of rotatable bonds and the polar surface area of the compounds are also within the standards compliant with the Veber's rule. Moreover, the calculated gastrointestinal absorption parameter indicates high absorption of carry from the gastrointestinal tract. Therefore, we can assume that these compounds, as potential drugs, will show adequate bioavailability after oral administration.

Conclusions:

All compounds showed very high cytostatic activity comparable to cisplatin. The presence of aliphatic or aromatic substituents on the amine fragment does not significantly affect the activity (relative to compound **4**), thus modification at this position can be efficiently used in optimization of the ADME-related physicochemical parameters such as solubility and lipophilicity, of *N*-(quinolin-8-yl)pyridine-3-sulfonamides derivatives.

Literature:

- Xie Y. et al *Bioorg. Med. Chem. Lett.* 18(1), **2008** 329-335
- K.-C. Tsai et al. *Bioorg. Med. Chem. Lett.* 19 **2009** 5665–5669
- Kalac et al., *iScience*, 23, **2020**, 101884
- A. Daina et al. *Sci. Rep.* 7, **2017**; :42717

ECMC
2022

The 8th International Electronic
Conference on Medicinal Chemistry
01-30 NOVEMBER 2022 | ONLINE